According to one recent study, tumor cell-derived ECs were refractory to inhibition of both the VEGF-A and basic fibroblast growth factor (bFGF and FGF-2) pathways.9 In fact, it is well established that tumor endothelial cells participate in the recruitment of stromal cells, including myeloid cells and bone marrow-derived cells, to generate a VEGF-A-independent pathway of tumor resistance to antiangiogenic treatment.27 Angiogenesis inhibitors block outside tumor vessels from growing into the solid tumor, thus terminating the supply of nutrients feeding tumor growth. The gene discussed is VEGFA; the disease is neoplasm.